Clinical Trials

BO41932 (TAPISTRY). unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay

Link :
Population : Advanced and unresectable or metastatic solid malignancy
Description : Targeted therapies or immunotherapy as single agents or in rational, specified combinations.
PI : D. Morgenstern
Centers Opened : SickKids
Phase : II
IIST/Pharma : Pharma